Our result indicated that the methylation status of DNAH17 was a promising biomarker for tumor thrombosis, which could provide more information about HCC features in the preoperative biopsy and help clinicians generate an individual treatment strategy. This evidence concerns the gene DNAH17 and hepatocellular carcinoma.